Oragenics Inc (OGEN.A)
28 Apr 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2011||Independent Chairman of the Board|
|57||2016||President, Chief Executive Officer, Director|
|58||2016||Chief Financial Officer, Treasurer, Secretary|
- BRIEF-Oragenics receives audit opinion with going concern explanation
- BRIEF-Oragenics board authorized to increase authorized shares of stock from 100 mln shares to 250 mln shares
- BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis
- BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017